An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease

NCT00986245 Phase 4 COMPLETED Results posted

1. In order to compare the benefit, side effects, and patient preference of Ropinirole prolonged release when used in once-daily or twice-daily dosing 2. In order to estimate the conversion rate of dopamine agonists into Ropinirole prolonged release

Details

Lead sponsor	Seoul National University Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	82
Start date	2009-09
Completion	2010-12

Conditions

• Parkinson Disease

Interventions

• Ropinirole Prolonged release

Primary outcomes

• Patient Preference — After 16 weeks or at last visit for early completion
  Patient preference between once-daily and twice-daily regimen

Countries

South Korea